In children and adolescents, hyperkinetic disorder (HD) with conduct disorder (CD) and without CD and attention-deficit/hyperactivity disorder (ADHD) is known to be comorbid with psychiatric disorders (anxiety, depression, aggression), some of which are related to disturbed serotonergic neurotransmission. The efficiency of serotonergic signalling relates to the concentration of the neurotransmitter in the synaptic cleft and is controlled by the serotonin transporter (5-HTT), which selectively removes serotonin out of the synaptic cleft.
= 7.603; P = 0.0211) and a significant overexpression of L/L in HD without CD (0.542: 0.333: 0.125; 2 = 9.127; P = 0.0092). To our knowledge, this is the first finding providing evidence for an association between the 5-HTT polymorphism and hyperkinetic disorder, implying that serotonergic neurotransmission might be affected in this desease. As a consequence, for a successful treatment of these patients one should now also consider drugs which specifically modulate serotonergic signalling such as selective serotonin reuptake inhibitors. Molecular Psychiatry (2001) 6, 235-238.
Attention-deficit/hyperactivity disorder (ADHD; DSM-IV, Diagnostic and Statistical Manual of the American Psychiatric Association) in accordance with hyperkinetic disorder (HD; ICD 10, International Classification of Diseases) has been noted to be comorbid with a variety of different psychiatric disorders. 3 These include oppositional defiant and conduct disorders, as well as anxiety, and affective and learning disorders. The prevalence rate of ADHD in various studies depends upon the definition of subtypes. ADHD can exist in distinct subtypes, each with its specific comorbidity. The prevalence rates were 6.8% for ADHD-all types, 3.2% for ADHD-inattentive type, 0.6% for ADHDhyperactive/impulsive type, and 4.7% for ADHD-combined type (F 90.0; ICD 10). 4 The widest estimation is 3-5% suggested by the DSM manual (American Psychiatric Association, 1980 Association, , 1987 . When the diagnosis of ADHD is made using a standardized structured interview with parents or teachers then the prevalence is very much higher: 14% according to Shekim et al, 5 reaching 19% in primary-school-age boys; 17% in the primary school boys investigated by Taylor et al. 6 The ICD (International Classification of Diseases) definition of hyperkinetic disorder has also been studied and has a lower prevalence in a population of primary school boys; 1.7% 6 and 1.3%, 7 respectively. After making allowance for gender differences and geographical variations, these figures would imply a point prevalence of about 1 in 200 for hyperkinetic disorder in the whole population of children. 8 Alterations in the activity of central serotonergic systems have been implicated in impulsive and aggressive behavior 9 and support the hypothesis of restricted serotonergic activity in aggressive and impulsive behaviors seen in hyperkinetic children with (HD+CD; F 90, 1; ICD-10) and without (HD; F 90.0; ICD-10) conduct disorders. In addition, Brown et al observed a significant negative correlation between platelet 5-HT uptake and impulsivity score in aggressive men. 10 Antidepressants enhance serotonergic signalling either by reducing the intraneuronal breakdown of serotonin by the degrading enzyme (mono amino oxidase inhibitors) or by blocking the reuptake of serotonin back into the presynaptic terminal (selective serotonin reuptake inhibitors, SSRIs, or tricyclic antidepressants, TCAs). These drugs bind to and inhibit the presynaptic serotonin transporter. This polypeptide selectively removes serotonin out of the synaptic cleft and thus plays a crucial role in serotonergic neurotransmission by controlling the concentration of free, active neurotransmitter in the synaptic cleft. 1 The human serotonin transporter (5-HTT) is encoded by a single gene on chromosome 17q11.2, and is expressed in brain and platelets. [11] [12] [13] Recently, a polymorphism in the promotor region upstream from the 5-HTT coding region has been described. This polymorphism is an insertion/deletion of a 44-bp sequence resulting in long (L) and short (S) alleles and affects transporter expression and function. The S variant has been shown to reduce 5-HTT gene transcription in a reporter gene construct and human lymphoblasts, resulting in reduced transporter levels and 5-HT uptake.
2 Consistently, in human healthy male volunteers the L variant was associated with more rapid initial platelet 5-HT uptake 14 and subjects with the L/L and L/S genotypes exhibit significantly higher platelet 5-HT levels than those with the S/S genotype. 15 When inpatients with major depression with psychotic features were randomly assigned to treatment with a fixed dose of fluvoxamine those patients carrying both homozygotes for the long variant (L/L) and heterozygotes (L/S) of the 5-HTT promoter showed a better response to the SSRI fluvoxamine than homozygotes for the short variant (S/S). 16 Interestingly, SSRIs are in discussion as successful treatment for some attention-deficit hyperactivity patients with comorbid disorder or pharmacological non-responders. [17] [18] [19] Taken together, these findings imply that an altered 5-HT function might be involved in hyperactivity disorders and prompted us to investigate a possible association between the 5-HTT polymorphism and HD±CD. Therefore, the present study was designed to test whether, in HD patients, allelic variations of the L allele (increased V max and better response to fluvoxamine) differ from healthy controls. The 5-HTT promoter genotypes for controls, HD subtypes and CD were determined by a PCR-based method.
Testing the subgroups for Hardy-Weinberg equilibrium, 20 Genotyping was carried out without knowledge of the diagnostic status. There were no differences between the individuals with the three genotypes in age, gender, or season of birth. The observed departure of the HD+CD patients from Hardy-Weinberg might reflect a phenomenon similar to that found in an association study between the dopamine D3 receptor gene and schizophrenia, in which the analysis of a Bal1 polymorphism in exon 1 of the dopamine D3 receptor gene revealed a significant excess of both forms of homozygotes in patients. 21 Here, it is argued that this might represent an example of heterozygote advantage because the presence of two different molecular forms of the receptor results in an increased ability to respond adaptively to variations in the environment occurring either during neural development or in adult life. Whether a similar explanation also holds true in our case, is not clear so far, but an independent replication of our findings might help corroborate such a hypothesis. Table 1 shows the distribution of genotypes of the 5-HTT promotor polymorphism in the whole group of patients with hyperkinetic disorders HD/HD+CD and healthy controls. The L/L genotype frequency was higher among HD/HD+CD patients compared with healthy controls ( 2 = 11.092, P = 0.004). Table 2 shows the distribution of genotypes of the 5- HT promotor polymorphisms in the group of healthy controls, in patients with hyperkinetic disorders without (HD) and with conduct disorders (HD+CD) and in patients with conduct disorders only ( 2 = 16.113; P = 0.013).
Testing was for homogeneity of genotype distribution as compared to controls (exact version of Pearson's 2 test; implementation by means of StatXact 3 For Windows. 22 The major finding of this study was a significantly higher frequency of the L/L genotypes of the 5-HT transporter gene polymorphism in patients with severe HD with (F 90.1; ICD-10) and without (F 90.0; ICD-10) conduct disorders. Both subtypes of children with hyperkinetic disorders F 90.0 (DSM-IV; 314.01, combined type; 2 = 9.127; P = 0.0092) and F 90.1 (with conduct disorder; 2 = 7.603; P = 0.0211) differ significantly from healthy controls.
The finding that the frequency of the L/L genotype was less enhanced in patients suffering from HD with CD is likely due to the fact that patients with conduct disorders only (ICD-10; F 91) do not differ from controls ( 2 = 1.097; P = 0.5912), which masks the enhanced L/L expression as seen in patients with HD without CD. This may imply that the patient group diagnosed for HD+CD also contains some patients suffering mainly from CD with only minor symptoms of HD or represents a yet undefined subgroup characterized by an enhanced homozygosity. This is to our best knowledge the first evidence suggesting that the functional polymorphism in the promotor region of the serotonin transporter gene is associated with HD, a result which also is consistent with the hypothesis that a lack of serotonin is involved in the etiology of hyperkinetic disorders as well as in aggressiveness, 23 impulsiveness, 24 ,25 depression or suicidal behaviour 26, 27 and obsessive-compulsive disorder. 28 Interestingly, depressive patients carrying the homozygous (L/L) or heterozygous (L/S) genotype, show a better response to SSRIs eg fluvoxamine than patients carrying the (S/S) genotype. 16 Since in some cases HD patients have been successfully treated with SSRIs, it would be interesting to know whether there exists a link between the therapeutic effect of SSRI treatment of HD and the 5-HTT L allele. If so, even though other factors are surely implicated, genotyping at the 5-HTT promoter may in future represent a promising tool to individualize the pharmacological treatment of severe hyperkinetic disorder with comorbid disorders, or those non responding to traditional pharmacotherapy.
Methods

Sample and questionnaire
One hundred and one inpatients, mean age 12.3 ± 3.5 years, were examined at the Central Institute of Mental Health (Department of Child and Adolescent Psychiatry) and diagnosed for Hyperkinetic Disorder with (HD+CD; F 90.1; n = 56) and without Conduct Disorder (HD; F 90.0; n = 24), and for Conduct Disorder (CD; F 91; n = 21) alone, according to the International Classification of Diseases (ICD-10) diagnostic criteria. F 90.0 is equivalent to DSM-IV 314.01 (combined type, Diagnostic and Statistical Manual of Mental Disorders). HD symptoms were generated from mother and father, followed by a direct interview with the child. Teacher and parent Conner's rating scales 29 were used to supplement the direct interview and determine HD diagnoses. Consensus diagnoses were obtained from a review of all ratings in the clinic conference. One hundred and sixty-three healthy controls (83 males, 80 females; mean age 11 ± 3.5 years) were recruited from different pediatricians who had observed the children from birth to age of examination and excluded any kind of psychiatric disorder. In addition, all controls were examined with the Conner's rating scale. Exclusion criteria were an IQ Ͻ 80 and evidence of medical or neurological disorders. The 5-HTT promoter genotype was determined by a PCR-based method. 12, [30] [31] [32] The ethnic make up of HD, HD+CD, CD and thus of the control samples in the present study was 100% Caucasians.
Genotyping
Genomic DNA was isolated from a 5-ml blood sample using the Qiamp(Quiagen, Chatsworth, CA, USA) DNA extraction kit and stored at −20°C.
Molecular Psychiatry
Serotonin-transporter-gene polymorphism was analyzed as follows: the biallele polymorphism in the 5Ј regulatory region of the SLC6A4 gene was amplified by polymerase chain reaction (PCR) with oligonucleotide primers DelF (5Ј-GGCGTTGCCGCTCTGAATGC-3Ј) and DelR (5Ј-GAGGGACTGAGCTGGACAACCAC-3Ј).
30,31 PCR reactions contained 100 ng genomic DNA, 10 pmol of each primer, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 0.01% gelatine, 200 M of dATP, dCTP, dTTP, 100 M of dGTP, 100 M of 7-deaza GTP, and 1 unit Taq polymerase in a total volume of 25 l. Cycling conditions were initial denaturation at 98°C for 3 min, followed by 35 cycles of denaturation at 94°C for 30 s, and a final elongation at 72°C for 10 min. PCR was carried out in a Perkin-Elmer Cetus 9600 thermal cycler. Fragment sizes were determined by comparison to molecular length standards. The 484-bp fragment of the biallele polymorphism was designated as 'S' and the 528-bp fragment as 'L' respectively.
